Traditional chemotherapy agents with targeted therapies improves survival in advance-stage lung cancer
A researcher from the Université de Montréal and the Maisonneuve-Rosemont Hospital has discovered the mechanism that prevents the regeneration of CD4+ T lymphocytes, which are white cells that are required for the proper functioning of the immune system. Published today in the prestigious journal Nature Immunology, this study by Dr. Martin Guimond is likely to
Full Post: New hope for transplant recipients and AIDS patients
The combination of traditional chemotherapy agents with targeted therapies called monoclonal antibodies showed no safety concerns and improved survival in patients with advanced non-small cell lung cancer according to a study presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology, sponsored by ASTRO, ASCO, IASLC and the University of Chicago.
The combination of bevacizumab and chemotherapy has been shown to increase the survival of patients with incurable non-small cell lung cancer. cetuximab has recently demonstrated improved survival when given in combination with platinum based chemotherapy. Based on this information, researchers from M.D. Anderson Cancer Center in Houston, Fred Hutchison Cancer Research Center and the Cancer Research and Biostatistical Clinical Trials Consortium (CRAB), both in Seattle, the Cancer Center of Kansas in Wichita, Kan., Central Illinois CCOP in Springfield, Ill., the University of Kansas in Kansas City, Kan., and U.C. Davis Cancer Center in Sacramento, all part of the South West Oncology Group, sought to investigate the safety and efficacy of the combination of the four drugs in this multi-center phase II clinical trial.
This study, the first reported study of these two targeted therapies (bevacizumab and cetuximab) with chemotherapy (carboplatin and paclitaxel), combined the four drugs as first-line therapy in advanced lung cancer patients. The goal of this study was to assess the safety of the four drug regimen. No safety concerns were seen when compared with other treatments. Additionally, in the 104 patients evaluated between August 2006 and September 2007, improved survival was observed.
“The combination of multiple targeted therapies in addition to chemotherapy may be the future of treatment in lung cancer,” said Edward Kim, M.D., lead author of the study and an assistant professor in the department of thoracic/head and neck medical oncology at M.D. Anderson Cancer Center. “Blocking more key cancer pathways such as the epidermal growth factor receptor and vascular endothelial growth factor may lead to improved cancer control.”
The four drug-combination of carboplatin and paclitaxel, with the targeted therapies bevacizumab (Avastin) and cetuximab (Erbitux), is safe and may improve survival for patients with advanced lung cancer, according to a cooperative group study led by The University of Texas M. D. Anderson Cancer Center. Presented today on the press program of the 2008 Chicago
Full Post: Combination of carboplatin and paclitaxel with bevacizumab and cetuximab proves safe for lung cancer treatment
Taking small tissue samples from patients with lung cancer and examining them under a microscope (a procedure called histology) is now being utilized to better tailor the chemotherapy treatments to improve survival in some patients with non-small cell lung cancer, according to a study presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology, cosponsored
Full Post: Tissue analyses indicate survival benefits for some lung cancer patients
Patients with locally advanced lung cancer who receive chemotherapy and proton therapy, a specialized form a radiation therapy only available in a few centers in the United States, have fewer instances of a serious side effect called bone marrow toxicity than patients who receive chemotherapy and another type of radiation therapy called intensity modulated radiation
Full Post: Proton therapy may reduce serious side effect of lung cancer treatment
Gefitinib, also known as Iressa, the once-promising targeted therapy for the treatment of non-small cell lung cancer, has proven as effective as chemotherapy as a second-line therapy for the disease with far fewer side effects, according to an international Phase III clinical trial, led by researchers at The University of Texas M. D. Anderson Cancer
Full Post: Gefitinib just as effective as chemotherapy for lung cancer
A team of cancer researchers from several Boston academic medical centers has discovered a potential treatment for a group of tumors that have resisted previous targeted therapy approaches. In their Nature Medicine report, which is receiving early online release, investigators from Dana-Farber Cancer Institute (DFCI), Massachusetts General Hospital (MGH) Cancer Center, and Beth Israel Deaconess
Full Post: Advance in K-Ras-mutated cancer research